Lilly's eczema drug shows durable long-term response in late-stage study

March 27 (Reuters) - Eli Lilly LLY.N said on Friday that its eczema drug showed durable results in a late-stage post-marketing study, such as  relief from persistent  itch for up to four years in patients with the skin condition.

Here are more details:

• A once-monthly injection of the drug, Ebglyss - approved in the United States in 2024 - showed durable response in patients with moderate-to-severe atopic dermatitis, which causes intense itching.

• The injectable treatment is approved for adults and children 12 years and older with moderate-to-severe eczema who cannot use topical therapies.

• In the study, majority of patients achieved near-complete skin clearance and itch relief with up to four years of continuous treatment, Lilly said.

• Ebglyss' safety in the first year of the study was consistent with its known profile, regardless of dosing frequency, and no new safety issues were observed, the company said.

• The study will continue for an additional year of treatment.

• Lilly last year reported results from another trial showing Ebglyss provided a durable response when dosed every four or eight weeks. The drugmaker said it has submitted the data to the U.S. Food and Drug Administration for a potential label update.